anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a computer assisted IV drug infusion administration device that permits only authorized and properly trained clinicians to operate the system.  &lt;P&gt;SOLUTION: A security system is integral with a sedation and analgesia system, and includes a computer assisted IV drug infusion administration device coupled with a secure user interface, or other security means, that can restrict and monitor user access to prevent unauthorized or improper use of the device. The system can also provide varying levels of access to the device so that different users may have different levels of access to system operations. The variety of access levels may prevent accidental or intentional misuse of the drug delivery system, while still permitting access to the required functionality. Data, such as usage statistics and procedural events associated with drug delivery, may be recorded in association with a user&#39;s personal identification information to help identify training needs and to identify possible misuse of access information.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
The present disclosure describes systems and methods for de-risking patient treatment by identifying medications or combinations of medications to be contraindicated for a specific indication. An analyzer executed by a processor of a computing device from a user may receive an identification of an indication (e.g. the subject of a clinical trial, or the diagnosis of a patient visiting a physician&#39;s office). The analyzer may retrieve, from an adverse event database, medication and co-medication information of patients that experienced a side effect corresponding to the indication. The analyzer may sort the retrieved medication and co-medication information to generate an ordered list of medications consumed by patients that experienced the side effect, and identify a first medication of the ordered list. A display module executed by the computing device may display, to the user, the first medication of the ordered list for contraindication from the clinical trial.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an additive which has excellent foam quality-improving effects and foam stabilizing capability, and enables a utilization to bubble-containing compositions used for various fields such as foods and drinks, cleaning agents (solid soap, kitchen detergent, body soap, shampoo, etc.), a resin, a civil engineering, and a boring.  &lt;P&gt;SOLUTION: The additive for a bubble-containing composition contains water-insoluble and/or carboxymethylcellulose in which a carboxymethyl substitution degree per anhydrous glucose unit is 0.05-0.4, or the salt. The additive contains carboxymethylcellulose which is noncrystalline, or the salt. The additive contains carboxymethylcelluse in which a ratio of a value from measurement with water serving as the disperse medium to a value from measurement with methanol serving as the disperse medium is 2.0 or more in a volume accumulating total 50% particle diameter measured by a laser diffraction/scattering type particle size distribution gauge, or the salt.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
FIELD: medicine. SUBSTANCE: device has synthetic-fiber tube- casing filled with mixture of liver tissue as suppressor and tissues of portal vein and pancreas with Langerhans&#39; islands. Longitudinal cut is made for entire length of tube-casing surface, and small cuts are made lengthwise and crosswise on ends of tube-casing. All tissues enclosed in tube-casing are fed with blood constantly by blood vessel with capillaries passing through device. EFFECT: enhanced treatment efficiency. 3 cl, 1 dwg
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for discriminating food being appropriate to skin improvements, by clarifying the factors of the food previously unknown by which skin states are affected.  &lt;P&gt;SOLUTION: The compositional ratio of essential fatty acid in food consumed daily until the date of investigation is used as an index for improvement of a skin state. As the composition ratio of essential fatty acid, a numerical value is preferably used, which is obtained by classifying the essential fatty acid into n-3 based fatty acid and n-6 based fatty acid, and by dividing an intake value of the n-6 based fatty acid by an intake value of the n-3 based fatty acid. This index is used, in order to carry out a discrimination as to whether a meal is appropriate to the improvement of the skin state. Specifically, when on the basis of the intake value of the n-3 based essential fatty acid, relatively lower the rate of the intake value of the n-6 based essential fatty acid is, the better its discrimination result would be. Such a discrimination result is attached to a makeup material.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
Embodiments are directed toward facilitating securely and efficiently providing medical-test results. Some embodiments enable secure and efficient mass testing by eliminating the requirement that patients provide personally identifying information after collection of their first testing specimen. The system enables delivering test results to such patients without the patients providing personally identifying information with specimens to be tested. The first time that a patient requests a medical test on a specimen, values representative of biometric characteristic thereof are recorded with personal information for the patient. Some embodiments facilitate looking up the patient&#39;s personal information by using values representative of biometrics obtained from the patient&#39;s subsequent specimens to be medically tested. Some embodiments facilitate security by storing personal information and biometric identifiers in separate data stores and linking records in those data stores by way of an identifier that does not identify the patient.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a labeling substance to effectively detect a double-stranded helical structure of a nucleic acid.  &lt;P&gt;SOLUTION: The nucleoside compound and a phosphoroamidite derivative thereof have a spacer of a peptide structure or a peptoid structure capable of reacting with a labeling compound in a nucleic acid base thereof. The phosphoroamidite derivative is introduced in the nucleic acid by the phosphoroamidite method and then the nucleic acid labeled by the reaction with the labeling compound is synthesized. The labeled nucleic acid can be used as the labeling substance to effectively detect a double-stranded helical structure of a nucleic acid. The labeling substance can be used in broad applications such as research, clinic, diagnosis, in vitro gene detection and in vivo gene detection, because of its excellent detection sensitivity of a nucleic acid, and the like.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to anesthesiology and resuscitation, and can be used in states accompanied by massive blood loss. For this purpose, 5 and 3 days prior to a surgery, autoblood is sampled in amount 10 % of circulating blood volume (CBV) in each sampling to be divided on plasma and erythrocyte concentrate. For 5 preoperative days, iron preparations are administered in a therapeutic dose. Also, the surgery is preceded with analysing patient&#39;s fluid deficiency. 40 minutes prior to the surgery, 12.5 % dicynone 500 mg, one volume of autoplasma are introduced, and infusion of a rated dose of 5 % glucose and 6 % hydroxyethyl starch (HES) 500 ml is started. If the intraoperative blood loss is suggested to be 15-30 % of the CBV, additionally 6 % HES 250 ml, prednisolone in dosage 2-4 mg/kg of body weight and one volume of erythrocyte concentrate are administered. If the estimated intraoperative blood loss exceeds 30 % of the CBV, the second volumes of autoplasma and erythrocyte concentrate, another introduction of dicynone in the same dosage, 6 % HES 250 ml, prednisolone in dosage 7 - 10 mg/kg of body weight are required. Within 30 and 60 minutes after the surgery, dicynone is injected in the same dosage. 5 hours after the surgery, filter drainage fluid is returned. 6 hours after the surgery, coagulation time is determined, and if observing no hypocoagulation, Clexane is introduced in a preventive dose. ^ EFFECT: method allows to provide early activation of erythropoiesis combined with improved erythrocyte morphology and blood haemostatic function, considerably reduced risk of complications connected with massive transfusion of donor blood products, as well as prevented edema of interstitial spaces and development of multiple-organ-failure syndrome due to maintained effective transcapillary exchange. ^ 5 tbl, 1 ex
A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. The compounds&#39; ability to inhibit RET kinase is quantified, i.e., their respective RET IC50 and EC50 values are described. One such compound, known as cyclobenzaprine and herein as SW-01, has been identified as RET-specific with an IC50 of 300 nM. SW-01 inhibits RET autophosphorylation and blocks the growth and transformation of thyroid cancer cell lines. It has been further tested in pancreatic cancer, breast cancer, and SCLC cell lines. The compounds show utility for inhibition of survival and proliferation of tumour cells.
PROBLEM TO BE SOLVED: To obtain the subject inhibitor to be readily administered orally, capable of eliminating a taste and a smell, by embedding finely granulated gristle of shark in an oil and fat matrix and coating the surface of the oil and fat matrix with a specific lipid. SOLUTION: Gristle of shark, preferably collected from Prionace glauca is finely granulated to give fine powder of gristle of shark comprising &gt;=99.5wt.% powder having $32μm particle diameter. The fine powder is embedded in a matrix of oils and fats (e.g. hardened oil of beef tallow) having preferably 42-56 deg.C melting point. The surface of the oil and fat matrix is coated with other oils and fats having a melting point different from that of the oils and fats to give a tumor newborn blood vessel inhibitor. The inhibitor has both anti-cancer action and analgesic action. When the inhibitor is used as an anti-cancer medicine, a dose is preferably about 1-10g/day as an of the active ingredient to an adult by oral administration.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a vaccine effective for prevention and treatment of feline infectious peritonitis (FIP).  &lt;P&gt;SOLUTION: This vaccine for the FIP is obtained by using an N-protein having a specific structure or a fragment thereof as an antigen. The desirable antigen is the N-protein derived from a specified virus type I strain (KU-2). The vaccine containing the N-protein provides preventive effects on wide FIPV. The N-protein is highly safe because of being free from an infection-enhancing epitope. The N-protein can achieve the preventive effects on a virus type I which causes 70% of the actual FIP.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a neurite outgrowth-promoting polypeptide based on a neuroglycan C and the use of the same.  &lt;P&gt;SOLUTION: This polypeptide holds at least the following amino acid sequence and consists of 12-400 amino acid residues. Asp Asp Leu Xaa Glu Glu Glu Glu Glu Glu Glu Asp (wherein, Xaa is Glu or Asp residue). The polypeptide holds at least the following amino acid sequence and consists of 39-400 amino acid residues. Cys Asp Leu Phe Pro Ser Tyr Cys His Asn Gly Gly Gln Cys Tyr Leu Val Glu Asn Ile Gly Ala Phe Cys Arg Cys Asn Thr Gln Asp Tyr Ile Trp His Lys Gly Met Arg Cys. The fused polypeptides obtained by bonding another polypeptide to these polypeptides, the nucleic acids encoding such polypeptides and a neurite outgrowth-promoting agent using such polypeptides as active ingredients are also provided.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
A system and method for communicating and validating patient information including medication delivery information in a care-giving facility is provided. A medical transaction carrier is used to communicate information regarding medication delivery and other patient information between a control system in communication with the care-giving facility&#39;s other information systems and a patient specific asset such as an infusion pump. All information carried by the medical transaction carrier is validated both at the patient specific asset and at the control system. This validation allows for positive control of all transactions even if a medical transaction carrier is lost. The medical transaction carrier may be a smartcard, a PDA such as a Palm™ Pilot, laptop computer, pager, mobile phone, or other device capable of storing and communicating information. The system may use either wired or wireless connections to communicate information between the components of the system.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a hair-washing agent composition which gives the advantage of the compounding of an amino acid type surfactant, can dissolve its defect of weak foamability, and improves the strength of hair.  &lt;P&gt;SOLUTION: This hair-washing agent composition comprises the following component (A): an alicyclic polyol, and the following component (B): an amino acid type surfactant. The component (A) is especially preferably inositol as the alicyclic polyol. The component (B) is especially preferably an anionic amino acid type surfactant as the amino acid type surfactant. A hair-treating method is characterized by applying the hair-washing agent composition to damaged hair.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide novel methods and compositions for protecting cats from infection by a broad range of FIV strains using a multiple FIV vaccine.  &lt;P&gt;SOLUTION: Multi-subtype FIV vaccines comprising either cell free whole virus or cell lines infected with viruses are described. Method for vaccinating cats with the subject vaccine composition are also described. Cats vaccinated according to the methods and compositions of the subject invention exhibit protective humoral and cellular immune responses to FIV when challenged with homologous or heterologous strains of FIV. The subject invention also pertains to novel feline cell lines that are susceptible to infection by FIV and their methods of use.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
An assay for ADP is described in which the ADP is detected by means of an ADP binding protein. A direct assay may be used in which labelled ADP, generated from a labelled precursor, is detected when the ADP is bound to the ADP binding protein. Alternatively, an indirect competition assay in which a labelled competitor of ADP is used. If ATP is present in the sample the assay may include a step of modifying the ATP, by using methionine adenosyl transferase (MAT), such that it cannot bind to the ADP binding protein. The ADP binding protein may be an antibody raised to the ADP analogue 3&#39; dephosphocoenzyme A (DePhosCoA) or HSP90, ADP dependent glucokinase or platelet membrane ADP binding protein. Further inventions comprise production of an antibody against DePhosCoA, an affinity column comprising DePhosCoA and using MAT to degrade ATP in an ADP assay sample.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an aggregate of a granular substance by a new shape-control method, which is conventionally impossible, and to provide a method for producing the aggregate.  &lt;P&gt;SOLUTION: A solid or hollow aggregate is provided, comprising aggregation of a granular substance of a metal oxide having a particle diameter of less than 0.1 μm, and a method for producing the aggregate is provided. The method includes dispersing the granular substance in a dispersion medium selected from an aqueous solvent, an alcohol- and an ether-based solvent to prepare a mixture liquid containing the granular substance. The granular substance is dispersed in the mixture liquid to obtain an average distance between surfaces of the granular substance satisfying L&lt;SB&gt;DLVO&lt;/SB&gt;≥L&lt;SB&gt;Woodcock&lt;/SB&gt;in the mixture liquid. The mixture liquid is changed into droplets of less than 100 μm, which are dried by vaporizing the dispersion medium.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE:The titled remedy containing 3,7-dihydro-3-methyl-1-(5-oxohexyl)-7- propyl-1H-purine-2,6--dione as an active constituent. CONSTITUTION:A remedy for cerebropathy, particularly memory disorder containing a compound expressed by the formula (propentofylline) as an active constituent. The cerebropathy may be primarily caused by the nervous system containing glial cells and the cerebrovascular system. As the mental and physical symptoms, dementia includes Alzheimer&#39;s dementia (progressive and recognized forgetfulness, disorientation of time and place and hypobulia rapidly worsening from the initial period of outbreak) and cerebrovascular dementia caused by cerebrovascular disorder. The prepentofylline is particularly effective for mem ory disorder in the various symptoms. The dose thereof is 100-1,500mg/day, and the continuous administration is possible due to the low toxicity. The rem edy can be administered by the methods of intravascular, intramuscular, oral and rectal administration.
The project was preceded by a pilot verification to select an appropriate approach for implementing the research design, including the development of a new VR application that took into account current technological advancements in this field. As part of the pilot verification, a custom application was created based on experiences with existing VR applications designed for therapeutic purposes for burn trauma patients in collaboration with Space s.r.o. Patients meeting the selection criteria (e.g., extent of burns, consent to participate in the study, and other relevant factors) were included in the study after the second dressing change in the dressing room. It was during these dressing changes that procedural pain occurred, first during the removal of old dressings and then during the removal of necrotic tissue and the application of new dressings. Each of these painful procedures was divided into two parts: 1) removal of old dressings; 2) removal of necrotic tissue and application of new dressings. In the study, pain sensation was repeatedly measured using the NPRS (Numeric Pain Rating Scale) and BSPAS (Burns Specific Pain Anxiety Scale) for both parts in at least 30 patients. Before each dressing change, it was randomly determined whether the VR would be used during the first part (removal of old dressings) or only during the second part (removal of necrotic tissue and application of new dressings). Additionally, the part involving VR was further assessed using a short immersion inventory, the Igroup Presence Questionnaire (IPQ). In the end, it was possible to evaluate the effect of VR on pain management during dressing changes in patients with burn trauma. The investigators will continue to measure several variables. The feeling of nausea will be assessed in a virtual environment on an ordinal scale from 0, indicating no nausea, to 10, indicating the worst imaginable nausea. Age will be recorded and categorized into six ordinal groups ranging from 18 to 70 years and older. The type of medications participants are currently taking will be recorded, categorized into six levels, including options ranging from none to five types of medications, such as strong opioids and analgesics. The total body surface area (TBSA) burned will be measured, with categories ranging from 0.4% to 45% or more. Additionally, the investigators will assess how the burn was caused, with categories including electro trauma, scalding, chemical trauma, frostbite, and flame burns. They will also evaluate participants\&#39; gaming and VR experience, determining whether participants consider themselves gamers, play games regularly, or have personal experience with virtual reality. These measurements aim to provide a detailed understanding of the participants´ conditions and their responses during the study.
The present invention relates to application of hydrotropic agents in making water-soluble and super-fast disintegrating tablets, buccal tablets, or sublingual tablets containing either cannabinoid molecules or psychedelics molecules. This invention comprises of sublingual tablets disintegrating in less than one minute. One aspect of this invention contains a hydrotropic agents&#39; composition to increase solubility of one or mixture of cannabinoid molecules. In this aspect, it may contain a cannabinoid composition comprising one or more cannabinoids molecules with or without presence of terpenes. It may also contain a disintegrant composition comprising of one or mixture of disintegrants. In another aspect, this invention contains one hydrotropic agent or a blend of hydrotropic agents to increase solubility of one or mixture of psychedelic molecules.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a skin softening agent having excellent softening effect on the skin, no skin irritation and excellent skin remaining properties on the skin.  &lt;P&gt;SOLUTION: This skin softening agent comprises a dihydroxy phenyl group-containing compound as an active ingredient. The skin softening agent prevents sclerema, excellent skin remaining properties on the skin and no skin irritation. A detergent composition comprises the skin softening agent. An external preparation composition comprises the skin softening agent.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
The aim of this project is to evaluate the impact of ASGE-FABES Program for the prevention of obesity in adolescents on physical activity, nutritional and mental health of overweight and obese adolescents. The program aims at promoting cognitive and behavioral skills for overweight and obese adolescents to lose weight in a healthy way, to promote healthy lifestyle behaviors, to make healthy choices, to increase their knowledge of nutrition and physical activity, to assume their own health responsibilities and to cope with stress. In the study, quot;experimental design type with randomized groups, pretest-posttest control group, repeated measurement\&quot; was used. The sample of the study consisted of 250 overweight and obese adolescents studying in the 6th grade of 10 secondary schools in Şişli district of Istanbul. The data of the study were collected using with Socio-Demographic Characteristics Form,Adolescent Nutrition Information Scale,Adolescent Physical Activity Information Scale, Adolescent Lifestyle Scale, Adolescent Healthy Lifestyle Choose Scale, Beck Anxiety Scale, Daily Food Consumption Form and Beverage Consumption Form.The data were collected before the application, at the first week after the application, and at the sixth and 12th months. Descriptive statistical tests, pearson chi-square tests, t-test in similar groups, repeated measures anova, and Cohen\&#39;s effect size tests were used in the analysis of the study. There was no significant difference between the experimental and control groups in terms of the descriptive characteristics, behavioral and cognitive variables of adolescents.